Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Waycart-6 is a branded generic formulation of deflazacort, a synthetic glucocorticoid corticosteroid. Developed and marketed by SBM Enterprises (also known as SBM Pharmaceuticals) in India, it contains 6 mg of deflazacort as the active ingredient. Deflazacort is a prodrug that is metabolized to its active form, 21-desacetyl-deflazacort, which binds to glucocorticoid receptors to exert potent anti-inflammatory and immunosuppressive effects. It is primarily indicated for the treatment of Duchenne muscular dystrophy (DMD), where it helps to maintain muscle strength and slow disease progression by reducing muscle inflammation. Additionally, Waycart-6 is used to manage a wide range of inflammatory and autoimmune conditions, including asthma, rheumatoid arthritis, severe allergic reactions, and various skin diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Waycart-6.